Comparative microRNA Profiling of Prostate Carcinomas with Increasing Tumor Stage by Deep Sequencing

Martin Hart¹, Elke Nolte², Sven Wach², Jaroslaw Szczyrba¹, Helge Taubert², Tilman T. Rau³, Arndt Hartmann³, Friedrich A. Gräßer¹, and Bernd Wullich²

Abstract

MicroRNAs (miRNA) posttranscriptionally regulate gene expression and are important in tumorigenesis. Previous deep sequencing identified the miRNA profile of prostate carcinoma versus nonmalignant prostate tissue. Here, we generated miRNA expression profiles of prostate carcinoma by deep sequencing, with increasing tumor stage relative to corresponding nonmalignant and healthy prostate tissue, and detected clearly changed miRNA expression patterns. The miRNA profiles of the healthy and nonmalignant tissues were consistent with our previous findings, indicating a high fidelity of the method employed. In the tumors, quantitative real-time PCR (qRT-PCR) analysis of 40 paired samples of prostate carcinoma versus normal tissue revealed significant upregulation of miR-20a, miR-148a, miR-200b, and miR-375 and downregulation of miR-143 and miR-145. Hereby, miR-375 increased from normal to organ-confined tumors (pT2 pN0), slightly decreased in tumors with extracapsular growth (pT3 pN0), but was then expressed again at higher levels in lymph node metastasizing (pN1) tumors. The sequencing data for miR-375 were confirmed by Northern blotting and qRT-PCR. The regulation for other selected miRNAs could, however, not be confirmed by qRT-PCR in individual tumor stages. MiR-200b, in addition to miR-200c and miR-375 reduced the expression of SEC23A. Interestingly, miR-375, found by sequencing in pT2 upregulated by us and others in tumor versus normal tissue, and miR-15a, found by sequencing in pT2 and pT3 and in the metastasizing tumors, target the phosphatases PHLP1 and PHLP2, respectively. PHLP1 and PHLP2 dephosphorylate members of the AKT family of signal transducers, thereby inhibiting cell growth. Coexpression of miR-15a and miR-375 resulted in downregulation of PHLP1/2 and strongly increased prostate carcinoma cell growth.

Implications: These genomic data reveal relevant miRNAs in prostate cancer that may have biomarker and therapeutic potential. Mol Cancer Res; 12(2); 250–63. ©2013 AACR

Introduction

Prostate carcinoma is the second most frequently diagnosed malignancy and a leading cause of cancer-related death in men worldwide (1). The underlying mechanisms resulting in invasive growth after dissemination of the primary tumor from the initial site in the prostate are not completely understood. MicroRNAs (miRNAs) are now recognized as contributing factors to the induction, growth, and metastasis of most tumors, including prostate carcinoma (for a review, see refs. 2 and 3). miRNAs are short, noncoding RNAs of approximately 19–25 nucleotides that bind preferentially to specific sequences in the 3′-untranslated region (3′UTR) of mRNAs, resulting in either translational repression or mRNA degradation. Interaction of the miRNAs with their mRNA target ultimately leads to reduced protein synthesis via association with the Argonaute (Ago-) containing RNA-induced silencing complex (for a review, see ref. 4).

We have previously established the miRNA profiles of prostate carcinoma in comparison with adjacent nonmalignant prostate tissue by a deep sequencing approach. We found that 33 miRNAs were deregulated more than 1.5-fold in the cancer samples (16 miRNAs upregulated, 17 downregulated; ref. 5; for a recent review on miRNA expression analysis in prostate carcinoma, see refs. 3, 6, 7). We subsequently showed that the levels of miR-375, miR-143, and miR-145 may be used as biomarkers to classify prostate carcinoma samples (8). On the basis of the sequence analysis, we have shown that myosin VI, which is induced in prostate carcinoma, is a target for the downregulated miRNAs miR-145 and miR-143. Furthermore, the SEC23A mRNA is a target for the induced miR-200c and miR-375 with
concomitant protein downregulation of SEC23A protein in prostate carcinoma. Accordingly, the overexpression of Sec23A resulted in reduced growth of prostate cancer cell lines (9). In addition, the downregulated miRNA mir-24 targets the ZNF217 mRNA: the subsequently induced ZNF217 protein is a known oncogene in other tumors and probably also plays a role in prostate carcinoma (10 and references therein).

As an extension of our recent analyses, we now compared nonmalignant prostate tissue with organ-confined tumors (pT2, pN0), tumors with extracapsular growth (pT3, pN0), and lymph node metastasizing (pN1) prostate carcinoma. We found that several of the previously identified upregulated miRNAs like miR-375 are strongly upregulated in the pT2/pT3 tumors and even more in lymph node metastasizing prostate carcinoma (pN1). By sequencing, miR-200b was upregulated in the pT2 to pT3 (pN0) samples but then showed reduced levels in the metastasizing tumors. This finding was confirmed by Northern blot analysis of the pooled RNAs used for the generation and sequencing of the miRNA cDNA libraries. However, by quantitative real-time PCR (qRT-PCR) analysis, this miRNA was also increased in the pN1 samples. Furthermore, we show that SEC23A is also a target for miR-200b (in addition to mir-200c and miR-375), and that the SEC23A expressed in prostate carcinoma is inversely correlated to the mir-200b/c levels. Importantly, we identify the PHLPPI and PHLPPI2 mRNAs as targets for miR-15a and miR-375. Both miR-15a and miR-375 were found induced in all tumor stages compared with normal tissue by sequencing and Northern blotting, but the increase could not be confirmed by qRT-PCR for miR-15a. The Pleckstrin homology domain and leucine rich repeat protein phosphatase (PHLPPI) enzymes dephosphorylate the AKT kinase, which, in the phosphorylated state, induces cell growth. Loss of, or reduction of, PHLPPI1 or PHLPPI2 and the ensuing increase in phosphorylation of AKT is an established cause for induction and/or progression of prostate carcinoma (11–13). Mir-15a and mir-375, therefore, play important roles in prostate carcinoma and may represent potential therapeutic targets. Furthermore, miRNAs hold the potential of being valuable biomarkers for the stratification of prostate carcinoma patients into clinically relevant risk groups.

Materials and Methods

Clinical samples
This study was approved by the local ethical review board and was performed according to the Declaration of Helsinki. Tissue samples were provided by the tissue biorepository at the University Cancer Center at the University Hospital of Erlangen. Only samples containing >70% tumor cells were included in the study. Gleason score, pathologic tumor stage, histologic diagnosis, and tumor-node metastasis classification was performed according to the guidelines of the Union International Contre le Cancer 2002 (14). The samples were reviewed by an experienced uropathologist (TTR) to confirm tissue identity, tumor cell content, and the absence of tumors cells in normal tissue preparation.

For the deep sequencing analysis, pooled normal and tumor tissue samples were used. The pool of organ-confined prostate carcinoma contained 10 tumor samples (pT2, pN0), prostate carcinoma with extracapsular growth contained seven samples (pT3, pN0), and the pool of lymph node metastasized prostate carcinoma contained three samples (pN1). Corresponding nonmalignant tissue from the same organ was prepared for all prostate carcinoma samples. An additional set of normal prostate tissue was prepared from five patients undergoing radical cystectomy for bladder cancer. The pathological review confirmed the absence of tumor cells in these samples.

A second, independent cohort of 40 cryoconserved tumor tissue samples with corresponding nonmalignant tissue was used for the validation of the sequencing results. The median age of the patients at the time of diagnosis was 67 years (51–77 years). The Gleason score of these tumors ranged from 5 to 9. The nonmalignant tissue, as defined by histologic examination, was prepared from the same organ as the tumor tissue. Clinical and pathologic characteristics of patients are summarized in Supplementary Table S1.

Illumina sequencing
A total of 45 tissue samples were pooled in five groups: Normal prostate, normal prostate adjacent to prostate carcinoma, pT2 prostate carcinoma, pT3 prostate carcinoma (pN0), and pN1 prostate carcinoma, and then the small RNA fractions were isolated to generate five cDNA libraries. The isolation of small RNA, sample preparation, next generation sequencing, and bioinformatic sequence analyses were carried out by Vertis Biotechnologie AG. In short, the total RNA preparations were examined by capillary electrophoresis, the small RNA samples were separated on denaturing 15% polyacrylamide gels, and the small RNA fractions containing RNAs with a length of 19–29 bases were eluted and used for the generation of the five cDNA libraries. These cDNA pools were sequenced on the Illumina HiSeq2000 system. The sequencing reads were mapped against miRBase V.15 using CLC workbench (CLC bio). Cross-mapped reads were randomly assigned to one of all possible cross-mapping locations. For the analysis of miRNA expression, a low expression cutoff was applied when then level of a given miRNA was below 0.1% in all four libraries analyzed. For the identification of deregulated miRNAs, we applied a 1.5-fold differential expression cutoff.

RNA extraction
Extracts from primary prostate carcinoma tissues were generated using TRIzol (Life Technologies). Extraction of total RNA and protein was carried out according to the manufacturer’s instructions.

Northern blotting
For Northern Blotting of the cell lines, total RNA was prepared using pepGOLD TriFast reagent (Peqlab) and used as described in the manufacturer’s manual. All RNA samples were separated in a 1% denaturing urea–polyacrylamide gel and transferred to nylon membrane Hybond
N (Amersham) by semidry electro blotting (30 minutes, 15 V; ref. 10). After chemical cross-linking of the RNA for two hours at 55°C, the radioactively labeled RNA probes were hybridized overnight on the target miRNAs. The synthesis and labeling of the radioactive miRNA probes was performed according to the manufacturer’s manual of miRVana Probe Construction Kit (Ambion). After washing the membrane twice for 15 minutes with 5 × saline sodium citrate (SSC) and 1% SDS, and twice for 15 minutes with 1 × SSC and 1% SDS, the membrane was exposed for at least 24 hours on a storage phosphor screen. The following day the phosphor screen was analyzed with the Phospholmager Typhoon (Amersham). Stripping of the nylon membrane was carried out using Stripping Buffer (5 mmol/L Tris pH 8; 0.2 mmol/L EDTA; 0.05% NaPP; 0.1% Denhardt’s solution) for 2 hours at 80°C. The sequences of RNA probes are shown in Supplementary Table S2.

miRNA qRT-PCR

For miRNA analysis, 10 ng of total RNA was reverse transcribed using the TaqMan miRNA Reverse Transcription Kit with the miRNA-specific RT primers contained in the TaqMan MicroRNA Assays (Life Technologies). RT-PCR was performed with the StepOnePlus Real-Time PCR System (Life Technologies) using sequence-specific primers and fluorescently labeled probes for miR-200b, mir-200c, miR-375, mir-145, mir-143, mir-148a, mir-15a, mir-20a, miR-93, and let-7c (Life Technologies). The PCR reactions were performed in triplicate in a final volume of 10 μL containing 1 × TaqMan Universal PCR Master Mix (Life Technologies), 1× TaqMan miRNA assay, and miRNA-specific primed cDNA, corresponding to an input amount of 300 ng total RNA per RT-PCR reaction. The thermal cycling conditions were as follows: 95°C for 20 seconds followed by 40 cycles of 95°C for one second and 60°C for 20 seconds. To quantify the miRNA expression in the tumor tissues, we used the relative quantification (ΔCt) method (13) with RNU6b serving as an internal control. RNA from PNF or LNCaP cells was examined miRNAs in PNF or LNCaP cells was arbitrarily set parallel on the same reaction plate, and the expression of the tumor tissues, we used the relative quantification (ΔCt) method (13) with RNU6b serving as an internal control. RNA from PNF for normalization.

qRT-PCR analysis of mRNA expression

cDNA synthesis was performed with the DyNano miRNA cDNA Synthesis Kit (Finnzymes Oy) using 200 ng of total RNA and random hexamer primers. The PCR primers for PHLPP1 (fwd 5'-GTC TCC AAG GTT GCA TCC CA-3', rev 5'-GAG TGG GAT TGC TAG GCC AG-3'), PHLPP2 (fwd 5'-GAG GCC AAT ACT CCC TTT CT-3', rev 5'-ACT CGT TCC CCA AAG TCT CGA AG-3'), and GAPDH (fwd 5'-CAT GAG AAG TAT GAC AAC AGC CT-3', rev 5'-AGT CCT TCC ACG ATA CCA AAG T-3') were purchased from Biomers (biomers.net). RT-PCRs were performed in triplicate with the StepOnePlus Real-Time PCR System (Life Technologies) in a total volume of 10 μL, which contained 1 × TaqMan Fast SYBR Green Master Mix (Life Technologies), 250 nmol/L forward primer, 100 nmol/L reverse primer, and 5 ng of cDNA with the following conditions: 95°C for 5 minutes, followed by 40 cycles of 95°C for 3 seconds and 60°C for 30 seconds. mRNA expression was quantified using the ΔΔCt using GAPDH as the internal control mRNA, and RNA from PNF for normalization.

Cell lines and tissue culture

The human 293T and the human prostate carcinoma cell lines DU145 and LNCaP cells were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ). The PNF cells represent normal prostate fibroblasts and were kindly provided by Prof. Gerhard Unteregger (Department of Urology, University of Saarland Medical School, Saarland, Germany). The identity of the cell lines had previously been confirmed by the Genomics and Proteomics Core facility of the German Cancer Research Center, Heidelberg, Germany. Cells were cultured as described previously (5).

Plasmids

The pSG5-miR-15a expression vector was cloned by PCR amplification of nucleotides 50623080–50623503 from chromosome 13 (NC_000013.10) and ligation of the resulting fragment into the EcoRI and BamHI restriction sites of the pSG5 plasmid (Stratagene). To obtain the pSG5–miR-200b expression construct, the nucleotides 1102390–1102757 of chromosome 1 (NC_000001.10) were amplified by PCR with specific primers and inserted into the pSG5 expression vector. The pSG5–miR-375 expression vector was described previously (9). The dual luciferase reporter plasmid pMIR-RNL, the pMIR-RNL-SEC23A reporter vector, and the appropriately mutated pMIR-RNL-SEC23A reporter constructs were described elsewhere (9). The nucleotides 39–905 of the PHLPP 1 3'UTR (accession number: NM_194449.3) and the nucleotides 1–968 of the PHLPP2 3'UTR (accession number: NM_015020.2) were amplified via PCR using specific primers from testis cDNA and inserted via the SpeI, SacI, or Nael restriction sites in pMIR-RL. The mutagenesis of the predicted target site seed sequences of pMIR-RL reporter constructs were performed with Quick-Change Site Directed Mutagenesis Kit (Stratagene), following the instructions of the manufacturer’s manual. The sequences of primers used for cloning and site-directed mutagenesis are shown in Supplementary Table S2.

Dual-luciferase assays, transfections, and Western blotting

The dual-luciferase assays were performed as described elsewhere (5) using the Dual-Luciferase Reporter Assay System in accordance with the manufacturer’s instructions (Promega). For transfection of prostate carcinoma cell lines,
approximately $2 \times 10^5$ LNCaP or DU145 cells per well were seeded out in 6-well plates. After 24 hours, the prostate carcinoma cells were transfected with 2 μg of plasmid DNA using jetPRIME (Polyplus Transfection). After 48 hours, cells were lysed with 2× sample buffer (130 mmol/L Tris/HCl, 6% SDS, 10% 3-mercaptop-1,2-propanediol, 10% glycerol, and 0.05% bromophenol blue). Thirty μg of extracted proteins were separated by 8.5% SDS-PAGE and transferred to a nitrocellulose membrane (Whatman, GE Healthcare) by Western blotting. The primary antibodies included anti-SEC23A monoclonal rat antibody 2H4-11 (5), anti-PHLPP1 (A300-661A; Bethyl Laboratories), anti-PHLPP2 (A300-660A; Bethyl Laboratories), and anti-GAPDH (Clone 14C10, NEB Cell signaling). Appropriate secondary antibodies were purchased from Sigma. Bands were visualized by enhanced chemiluminescence (Roht) with Amersham Hyperfilm ECL (GE Healthcare Europe GmbH). Western blots were quantified by Quantity One analysis software (Bio-Rad).

Cell proliferation assay

In 6-well plates, $2 \times 10^5$ DU145 or LNCaP cells per well were seeded out. After 24 hours, the cells were transfected with 2 μg of plasmid DNA using jetPRIME (Polyplus transfection) or with 1.5 μg miRNA inhibitor (Qiagen) using HiPerFect transfection reagent (Qiagen) based on the manufacturer’s instructions. For all transfections, appropriate negative controls were included. In addition, at the 0-hour time point, the cells were harvested. At 24, 48, and 72 hours posttransfection time points, the remaining cells were collected and counted by Flow Cytometry using FACS-Canto II (BD Biosiences).

Data analysis and statistical methods

Statistical evaluation of the luciferase assays was performed with SigmaPlot 10 (Systat). Statistical analyses of real-time qRT-PCR experiments (Kruskal–Wallis test) and of cell proliferation experiments (two-way ANOVA) were performed using GraphPad Prism 6.0 (Graph Pad software). All statistical tests were performed as two-sided with P-values < 0.05 considered as significant.

Results

miRNA profiling of normal prostate tissues and prostate carcinoma at various stages of malignancy

We performed miRNA-expression profiling of nonmalignant prostate tissue and prostate carcinoma at various stages of malignancy by deep sequencing. We additionally compared the miRNA expression between corresponding nonmalignant prostate tissue adjacent to prostate carcinoma and healthy prostate tissue that was derived from patients undergoing radical cystectomy due to bladder cancer. An initial analysis indicated that none of the minor transcript miRNAs (termed *miRNAs in miRBase V.15) would withstand the applied low expression and differential expression cutoffs. Therefore all of the *miRNAs were excluded from further analyses. The results of the deep sequencing analysis (covering only major miRNA transcripts) are shown in Supplementary Table S3. The relative expression levels of the miRNAs were comparable and also matched the results of our previous study of healthy prostate tissue (5). The profiling of the two pools of nonmalignant prostate tissue yielded comparable results for the samples from the corresponding nonmalignant part of the prostate and healthy prostate tissue obtained after radical cystectomy. Furthermore, the relative abundance of miRNAs in the nonmalignant tissue pools was essentially the same as described in our earlier analysis (5), in which the 30 most abundant miRNAs were present at the same relative level in all three libraries, indicating that the method yields reproducible results. In the following paragraphs, we refer to healthy or normal prostate tissue adjacent to prostate carcinoma.

Next, the normal tissue samples were compared with organ-confined prostate carcinoma (pT2, pN0), prostate carcinoma with extracapsular growth (pT3, pN0), and prostate carcinoma with local lymph node metastases (pN1). Figure 1 shows the miRNAs that were up- or downregulated at least 1.5-fold in one of the tumor samples. Most miRNAs that were previously found to be induced (5) were again upregulated; most notable were the miRNAs miR-375, miR-200b/c, miR-148a, miR-141, miR-106a/b, miR-21, and miR-20a, whereas some like let-7a/e remained unchanged in the present analysis. The strongest induction was noted for miR-375, with the highest relative levels in the metastasized samples (pN1) as compared with the other tumor samples (pT2, pN0; pT3, pN0). Likewise, miR-148a/b and miR-21 showed a strong upregulation in the metastasizing versus nonmetastasized tumors. This is depicted in Fig. 1A. Table 1 lists the miRNAs that displayed more than 1.5-fold change within two libraries. The complete set of data is given in Supplementary Table S3, which lists all miRNAs that were present in at least one of the libraries with a relative amount of sequence alignments of 0.1%. Interestingly, some miRNAs like miR-200b, miR-200c, miR-25, miR-106a, miR-17, or miR-93 showed increasing miRNA expression levels from healthy to pT2 (pN0) to pT3 (pN0) samples but then a reduction in the lymph node metastasizing tumors. Likewise, the relative expression levels of several upregulated miRNAs like miR-93, miR-18a, miR-20a, or miR-20b were decreased in lymph node metastasizing samples compared with the amounts detected in normal samples. These results were confirmed by Northern blot analysis of the RNA samples used for the generation of the library. Notably, let-7b and let-7c, the latter previously described to be induced in medium grade prostate carcinoma (15, 16), were further upregulated in the pT3 (pN0) cases but then reduced below the levels of normal prostate in the lymph node metastasizing tumors (Fig. 1). The strongest relative downregulation was observed for let-7e and miR-205 (Fig. 1B). A strong downregulation of miR-205 in prostate carcinoma was also observed by Boll and colleagues (17). We again noted reduced levels of miRNAs like miR-143, miR-145, miR-320a, or miR-424 as previously described (5). In comparison with our previous profiling, some miRNAs, such as miR-223, miR-221, or miR-27a, remained unchanged in this analysis.
Next, we selected eight miRNAs for further validation. The most pronounced up- or downregulation was observed for miR-375 and let-7e. miR-143 and miR-145 are well-known tumor suppressor miRNAs and a reduced expression of these miRNAs has been described multiple times (reviewed in ref. 3). miRNAs miR-20a and miR-200b
Table 1. Deregulated miRNAs identified by deep sequencing in organ-confined (pT2, pN0), extracapsular growing (pT3, pN0), and lymph node metastasizing (pN1) prostate carcinoma

<table>
<thead>
<tr>
<th>miRNA</th>
<th>Relative expression, %</th>
<th>Fold change</th>
<th>Relative expression, %</th>
<th>Fold change</th>
<th>Relative expression, %</th>
<th>Fold change</th>
</tr>
</thead>
<tbody>
<tr>
<td>hsa-miR-106a</td>
<td>0.08</td>
<td>1.81</td>
<td>0.11</td>
<td>2.59</td>
<td>0.08</td>
<td>1.78</td>
</tr>
<tr>
<td>hsa-miR-106b</td>
<td>0.14</td>
<td>2.57</td>
<td>0.25</td>
<td>4.68</td>
<td>0.27</td>
<td>5.06</td>
</tr>
<tr>
<td>hsa-miR-10a</td>
<td>0.07</td>
<td>1.45</td>
<td>0.10</td>
<td>1.98</td>
<td>0.06</td>
<td>1.18</td>
</tr>
<tr>
<td>hsa-miR-141</td>
<td>3.89</td>
<td>2.73</td>
<td>3.47</td>
<td>2.43</td>
<td>3.98</td>
<td>2.79</td>
</tr>
<tr>
<td>hsa-miR-148a</td>
<td>0.94</td>
<td>3.30</td>
<td>1.20</td>
<td>4.23</td>
<td>1.22</td>
<td>4.29</td>
</tr>
<tr>
<td>hsa-miR-148b</td>
<td>0.07</td>
<td>1.76</td>
<td>0.08</td>
<td>2.20</td>
<td>0.12</td>
<td>3.06</td>
</tr>
<tr>
<td>hsa-miR-15a</td>
<td>0.94</td>
<td>1.77</td>
<td>0.89</td>
<td>1.69</td>
<td>0.89</td>
<td>1.67</td>
</tr>
<tr>
<td>hsa-miR-17</td>
<td>0.30</td>
<td>1.79</td>
<td>0.44</td>
<td>2.58</td>
<td>0.25</td>
<td>1.47</td>
</tr>
<tr>
<td>hsa-miR-186</td>
<td>0.16</td>
<td>1.40</td>
<td>0.17</td>
<td>1.51</td>
<td>0.17</td>
<td>1.48</td>
</tr>
<tr>
<td>hsa-miR-18a</td>
<td>0.08</td>
<td>1.19</td>
<td>0.13</td>
<td>1.89</td>
<td>0.07</td>
<td>1.00</td>
</tr>
<tr>
<td>hsa-miR-191</td>
<td>0.53</td>
<td>1.35</td>
<td>0.72</td>
<td>1.85</td>
<td>0.51</td>
<td>1.31</td>
</tr>
<tr>
<td>hsa-miR-195</td>
<td>0.48</td>
<td>1.61</td>
<td>0.57</td>
<td>1.94</td>
<td>0.52</td>
<td>1.76</td>
</tr>
<tr>
<td>hsa-miR-196b</td>
<td>0.09</td>
<td>1.98</td>
<td>0.11</td>
<td>2.23</td>
<td>0.10</td>
<td>2.08</td>
</tr>
<tr>
<td>hsa-miR-199b</td>
<td>0.26</td>
<td>1.40</td>
<td>0.30</td>
<td>1.67</td>
<td>0.37</td>
<td>2.01</td>
</tr>
<tr>
<td>hsa-miR-200a</td>
<td>0.31</td>
<td>2.81</td>
<td>0.30</td>
<td>2.75</td>
<td>0.28</td>
<td>2.59</td>
</tr>
<tr>
<td>hsa-miR-200b</td>
<td>0.20</td>
<td>3.00</td>
<td>0.32</td>
<td>4.71</td>
<td>0.18</td>
<td>2.71</td>
</tr>
<tr>
<td>hsa-miR-200c</td>
<td>0.55</td>
<td>1.82</td>
<td>0.90</td>
<td>2.99</td>
<td>0.46</td>
<td>1.54</td>
</tr>
<tr>
<td>hsa-miR-20a</td>
<td>0.89</td>
<td>1.60</td>
<td>1.12</td>
<td>2.01</td>
<td>0.54</td>
<td>0.97</td>
</tr>
<tr>
<td>hsa-miR-20b</td>
<td>0.19</td>
<td>1.31</td>
<td>0.28</td>
<td>1.94</td>
<td>0.11</td>
<td>0.76</td>
</tr>
<tr>
<td>hsa-miR-21</td>
<td>2.00</td>
<td>1.45</td>
<td>2.52</td>
<td>1.84</td>
<td>4.86</td>
<td>3.54</td>
</tr>
<tr>
<td>hsa-miR-23a</td>
<td>0.65</td>
<td>1.01</td>
<td>0.81</td>
<td>1.26</td>
<td>0.98</td>
<td>1.52</td>
</tr>
<tr>
<td>hsa-miR-25</td>
<td>0.18</td>
<td>1.93</td>
<td>0.28</td>
<td>2.90</td>
<td>0.19</td>
<td>2.00</td>
</tr>
<tr>
<td>hsa-miR-30d</td>
<td>0.20</td>
<td>1.42</td>
<td>0.24</td>
<td>1.68</td>
<td>0.20</td>
<td>1.38</td>
</tr>
<tr>
<td>hsa-miR-30e</td>
<td>0.13</td>
<td>1.59</td>
<td>0.12</td>
<td>1.46</td>
<td>0.08</td>
<td>0.97</td>
</tr>
<tr>
<td>hsa-miR-363</td>
<td>0.27</td>
<td>1.61</td>
<td>0.34</td>
<td>2.06</td>
<td>0.25</td>
<td>1.49</td>
</tr>
<tr>
<td>hsa-miR-375</td>
<td>1.13</td>
<td>3.09</td>
<td>1.03</td>
<td>2.80</td>
<td>2.17</td>
<td>5.93</td>
</tr>
<tr>
<td>hsa-miR-92a-1</td>
<td>0.15</td>
<td>1.54</td>
<td>0.17</td>
<td>1.67</td>
<td>0.11</td>
<td>1.15</td>
</tr>
<tr>
<td>hsa-miR-92a-2</td>
<td>0.12</td>
<td>1.40</td>
<td>0.13</td>
<td>1.52</td>
<td>0.10</td>
<td>1.09</td>
</tr>
<tr>
<td>hsa-miR-93</td>
<td>0.39</td>
<td>1.37</td>
<td>0.71</td>
<td>2.49</td>
<td>0.29</td>
<td>1.02</td>
</tr>
</tbody>
</table>

**Downregulated miRNAs**

<table>
<thead>
<tr>
<th>miRNA</th>
<th>Relative expression, %</th>
<th>Fold change</th>
<th>Relative expression, %</th>
<th>Fold change</th>
<th>Relative expression, %</th>
<th>Fold change</th>
</tr>
</thead>
<tbody>
<tr>
<td>hsa-let-7b</td>
<td>1.19</td>
<td>1.02</td>
<td>1.41</td>
<td>1.22</td>
<td>0.71</td>
<td>0.62</td>
</tr>
<tr>
<td>hsa-let-7c</td>
<td>0.71</td>
<td>0.81</td>
<td>1.00</td>
<td>1.15</td>
<td>0.54</td>
<td>0.62</td>
</tr>
<tr>
<td>hsa-let-7e</td>
<td>0.04</td>
<td>0.29</td>
<td>0.07</td>
<td>0.51</td>
<td>0.03</td>
<td>0.21</td>
</tr>
<tr>
<td>hsa-miR-100</td>
<td>0.47</td>
<td>0.78</td>
<td>0.63</td>
<td>1.03</td>
<td>0.41</td>
<td>0.67</td>
</tr>
<tr>
<td>hsa-miR-130a</td>
<td>0.17</td>
<td>0.75</td>
<td>0.12</td>
<td>0.56</td>
<td>0.21</td>
<td>0.96</td>
</tr>
<tr>
<td>hsa-miR-143</td>
<td>31.61</td>
<td>0.79</td>
<td>25.82</td>
<td>0.64</td>
<td>25.95</td>
<td>0.65</td>
</tr>
<tr>
<td>hsa-miR-145</td>
<td>1.27</td>
<td>0.86</td>
<td>1.00</td>
<td>0.68</td>
<td>0.73</td>
<td>0.49</td>
</tr>
<tr>
<td>hsa-miR-205</td>
<td>0.16</td>
<td>0.72</td>
<td>0.15</td>
<td>0.71</td>
<td>0.09</td>
<td>0.41</td>
</tr>
<tr>
<td>hsa-miR-320a</td>
<td>0.10</td>
<td>0.82</td>
<td>0.12</td>
<td>0.99</td>
<td>0.06</td>
<td>0.52</td>
</tr>
<tr>
<td>hsa-miR-424</td>
<td>0.24</td>
<td>0.84</td>
<td>0.19</td>
<td>0.68</td>
<td>0.17</td>
<td>0.61</td>
</tr>
<tr>
<td>hsa-miR-451</td>
<td>0.20</td>
<td>1.07</td>
<td>0.11</td>
<td>0.58</td>
<td>0.13</td>
<td>0.68</td>
</tr>
</tbody>
</table>

**NOTE:** miRNAs listed were deregulated by at least 1.5-fold compared with the normal tissue. Relative expression refers to the percentage of miRNA deep sequencing reads in the respective cDNA library.
exhibited the regulation pattern of stage-specific increasing expression with a dramatic reduction of expression in lymph node metastasizing prostate carcinoma. We, furthermore, selected miRNAs miR-15a and miR-148a because the functional role of these miRNAs in primary prostate carcinoma cases is currently under discussion (18–20).

The changes in the expression levels of let-7c, miR-15a, miR-20a, miR-143, miR-145, miR-148a, miR-200b, and miR-375 observed by sequencing were analyzed by Northern blot analysis of the pooled RNAs employed in the generation of the cDNA libraries for sequencing as shown in Supplementary Fig. S1. We also carried out a qRT-PCR analysis for miRNAs let-7c, miR-15a, miR-143, miR-145, and miR-148a in 40 pairs of prostate carcinoma and corresponding nonmalignant samples. There were significantly different expression levels for miR-143, miR-145, miR-148a, miR-20a, miR-200b, and miR-375 ($P = 0.008; P < 0.001; P < 0.001; P = 0.020; P < 0.001; P < 0.001$; Kruskal–Wallis test) but not for miR-15a and let-7c ($P = 0.320$ and $P = 0.451$; Kruskal–Wallis test) at comparing prostate carcinoma and the corresponding normal nonmalignant sample (Supplementary Fig. S2). The quantification of the Northern blots and the corresponding qRT-PCR data from the above mentioned 40 primary tumor samples are shown in Fig. 2. The Northern blots partially reflect the changes in expression levels obtained by sequencing, in particular, for miR-375, which showed an increase from normal to pT2, a slight decrease from pT2 (pN0) to pT3 (pN0), and a strong additional increase from pT3 (pN0) to the

![Figure 2](image_url). Validation of the miRNA expression profile by quantification of Northern blotting and qRT-PCR. The expression of eight miRNAs was assessed by Northern blotting in pooled RNA preparations (black bars) and by qRT-PCR in 40 pairs of tumor tissue and corresponding normal tissue (box and whisker plots).
metastasizing samples (pN1). We point out that miR-375 is increased in all tumor samples by sequencing, Northern blotting, and qRT-PCR. The initial increase of miR-200b and miR-200c levels observed from normal to the pT2 (pN0) to pT3 (pN0) cases, followed by a decrease in the lymph node metastasizing cases, were confirmed by Northern blotting but not by qRT-PCR.

For miR-15a, we found by sequencing an increase in all tumor entities. In the Northern blots, the level dropped from pT3 (pN0) to pN1 but was still higher than in a normal tissue. This increase was not confirmed by qRT-PCR (Fig. 2).

For miR-145, by sequencing, we found a stepwise decrease in the expression from normal to pT2, pT3, and pN1 samples. The identical regulation pattern was observed in Northern blotting but could not be confirmed in qRT-PCR. For miR-143, we observed by sequencing an analogous reduction in expression from normal to pT2 to pT3 tumors but no further reduction in pN1 samples. The Northern blot analysis, however, displayed in addition a continuous reduction from pT3 to pN1 samples but this regulation could not be confirmed in qRT-PCR. For let-7c, we detected by sequencing and Northern blotting a decreased expression in pT2 tumors, an increase even above the expression levels in normal tissue for pT3 tumors with a subsequent and strong decrease in expression in pN1 tumors but this regulation could not be confirmed in qRT-PCR. For miR-148a, both by sequencing and Northern blotting, we detected an increase in the expression from normal to pT2 to pT3 tumors. The sequencing analysis indicated a further increase in pN1 tumors whereas the Northern blotting analysis suggested a reduction in pN1 tumors, but this regulation could not be confirmed in qRT-PCR.

**SEC23A is a target for miR-200b**

The SEC23A mRNA is a target for both miR-200c and miR-375 (9, 21). The 3’UTR of the SEC23A mRNA has two predicted binding sites (Fig. 3A), which are identical for miR-200b and miR-200c. We could previously show that miR-200c functionally interacts with one of these binding sites (9). In the present analysis, we found an upregulation of miR-200b, which shares the seed sequence with miR-200c. The reporter gene experiments confirmed a negative regulatory effect of miR-200b on the SEC23A 3’UTR (Fig. 3A). The site-directed mutation of the two predicted miRNA binding sites revealed that only one of them, the binding site which we could confirm to be a target of miR-200c, is also the target site for miR-200b (nt 855, Fig. 3A). Ectopic expression of miR-200b in LNCaP or DU145 prostate carcinoma cells resulted in a 40% downregulation of the SEC23A protein (Fig. 4A). The expression of miR-200b was verified by Northern blotting (Supplementary Fig. S2A and S2B).

**PHLPP1 and PHLPP2 are targets for miR-15a and miR-375, respectively**

In both our previous and the present analyses, miR-375 exhibited the strongest upregulation of all miRNAs in the prostate carcinoma samples. The TargetScan v4.1 prediction algorithm identified PHLPP1 as a high-ranked target for miR-375. PHLPP1 is recognized as a tumor suppressor with a prominent role in suppressing oncogenic signaling pathways, including the AKT pathway (for review, see refs. 22, 23). Interestingly, another member of this family of phosphatases, PHLPP2, is a potential target of miR-15a, which we found to be upregulated in deep sequencing and Northern blotting in all prostate carcinoma samples. Therefore, we performed reporter gene analyses to test whether both PHLPP genes are targets of miRNAs deregulated in prostate carcinoma. For both, the PHLPP1 (Fig. 3B) and PHLPP2 (Fig. 3C) 3’UTRs, we observed a significant reduction in reporter gene activity when coexpressed with the respective miRNAs. The expression construct for miR-375 was previously described (Supplementary data in ref. 5); the ectopic expression of miR-15a from the corresponding pSG5 construct is shown by Northern blotting Supplementary Fig. S3A. The binding sites (seed sequences) for the two miRNAs were subsequently mutated, and we could show that the mutated reporter gene constructs were no more responsive to the corresponding miRNAs (Fig. 3B and C). The two miRNAs were then overexpressed in DU145 and LNCaP prostate carcinoma cells, and the protein expression of PHLPP1 or PHLPP2 was determined by Western blotting. As shown in Fig. 4B, miR-375 reduced the levels of PHLPP1 in DU145 and LNCaP cells to 60% as compared with the controls. Likewise, we observed a 40% reduction of PHLPP2 by miR-15a (Fig. 4C).

To corroborate the above findings, we assessed the expression of the SEC23A, PHLPP1, and PHLPP2 mRNAs in primary prostate carcinoma samples and the corresponding normal tissue. As shown in Supplementary Fig. S4, the PHLPP2 mRNA was significantly reduced from normal to pT2 prostate carcinoma, whereas the SEC23A and the PHLPP1 mRNAs were expressed at lower levels in the tumor samples. However, this reduction did not reach significance.

**Coexpression of miR-15a and miR-375 increases the growth of prostate carcinoma cell lines**

As it is known that PHLPP protein phosphatases are potent inhibitors of proliferative signaling pathways, we tested the effects of miR-15a and miR-375 overexpression on the proliferation of prostate carcinoma cell lines. Both miRNAs were overexpressed either alone or combined in the LNCaP and DU145 cell lines. For miR-375, we had previously shown that its expression is increased in DU145 and LNCaP prostate carcinoma cell lines as compared with prostate normal fibroblasts (PNFs; Fig. 3 in Szczesny and colleagues; ref. 5). The endogenous level of miR-15a in PNFs versus the DU145 and LNCaP cell lines is shown in Supplementary Fig. S3B. As can be seen in Fig. 5A, the coexpression of miR-15a and miR-375 significantly enhanced cell proliferation of both cell lines (P < 0.001; two-way ANOVA). We also inhibited the expression of miR-15a and miR-375 using antisense
oligonucleotides. As shown in Fig. 5B, the joint knock-down of miR-15a and miR-375 reduced cell proliferation after 72 hours (P < 0.0001; two-way ANOVA). As LNCaP cells do not express appreciable amounts of miR-375 (5), we only carried out a knockdown experiment in DU145 cells. We noticed a reduction of cell growth at the 72-hour time point when the empty pSG5 vector was transfected into the DU145 cells (Fig. 5A). Additional experiments confirmed that this represents a specific effect of the pSG5 control vector in DU145 cells (Supplementary Fig. S5). However, the cotransfection of miR-15 and miR-375 in DU145 cells clearly leads to an induction of cell growth compared with the empty control vector and the single transfections.

Figure 3. Luciferase reporter gene assays. For the 3’UTR regions of SEC23A (A), PHLPP1 (B), and PHLPP2 (C), a schematic representation of the reporter gene construct with the predicted miRNA interaction site, as well as the mutated interaction site, is shown. The reporter gene constructs were expressed with or without miRNA-expression constructs in the indicated combinations. Results represent the mean of four independent experiments performed in duplicates. ***, P < 0.001.
Discussion

The results presented in this manuscript confirm and extend our previous miRNA-expression profiling carried out by high-throughput sequencing (5). The comparison of the samples derived from the corresponding nonmalignant tissue adjacent to prostate carcinoma and healthy prostate tissue derived from cystectomy specimens yielded essentially the same expression profiles as previously described for corresponding normal prostate tissue (5). Likewise, the majority of all deregulated miRNAs were repeatedly found in this analysis, indicating that the methods yield reproducible results. The overall expression of miR-375 increased in the tumor samples compared with normal tissue irrespective of the tumor stage. We found an initial increase from normal to pT2 (pN0), then a slight drop from pT2 (pN0) to pT3 (pN0), and then a strong increase in the pN1 samples. This increase in miR-375 was initially reported in our earlier study (5), as well as by Schaefer and colleagues (24) and Martens-Uzunova and colleagues (25). Two recent studies reported increased serum levels of miR-375 (and miR-141) in patients with metastatic prostate carcinoma (26, 27). In contrast, a miRNA profiling approach based on high-throughput sequencing by Watahiki and colleagues did not find an increase of miR-375 in metastatic prostate carcinoma (28). Other studies using microarray analysis also did not find an induction of miR-375 in prostate carcinoma (reviewed in refs. 3 and 29). However, we were able to verify our deep sequencing analysis by Northern blotting analysis. By sequencing, the levels of miR-200b and miR-200c gradually increased with the malignancy of the samples but then dropped to lower levels in the metastasizing samples. This observation was confirmed for miR-200b by Northern blotting analysis of the samples used for the generation of the cDNA libraries. Using a set of 40 corresponding pairs of primary tumor samples and the nonmalignant tissues, we observed an increase in all tumor samples for miR-200b. Future experiments employing larger numbers of cases will have to be carried out to address this issue. The significance of miR-200b/c overexpression as found here is highlighted by the fact that the overexpression of miR-200 induced migration in PC3 cells (30) and that downregulation of SEC23A by miR-200c has been described as...
a metastasis-promoting event (31), corroborated by our finding that SEC23A is also a target for miR-375 (9). Our observation that miR-200b and miR-200c first increase in their expression with the stage of malignancy but then decrease with progression to a metastasizing tumor would be in line with their proposition that there is a shift in SEC23A levels from nonmetastatic to metastatic tumors (21). In addition, Kong and colleagues showed that the miR-200 family regulates epithelial–mesenchymal transition, adhesion, and invasion of prostate cancer cells which are characteristic features of metastatic cells (32).

Recent data also describe elevated serum levels of miR-375 and miR-141 as predictors for poor prognosis (27) or metastasis (26) reviewed in reference 6. MiR-141 is found upregulated in primary tissues in a variety of studies including ours (2, 25), and inclusion of miRNA expression data significantly improves the accuracy of markers like prostate-specific antigen in the diagnosis or prediction of tumor outcome (33). The induction of the miR-106b-93-25 cluster is in line with the poor prognosis described by others (34). Previously, miR-190 was shown to downregulate PHLPP1 (35). In our analysis, miR-190 was not deregulated in the different stages of prostate carcinoma that were analyzed. Instead, we found that miR-375 and miR-15a coordinately downregulate PHLPP1 and PHLPP2, respectively. Genomic deletion of the PHLPP1 and PHLPP2 genes was described as being correlated with the induction of prostate carcinoma (11–13) and a PTEN/PHLPP1 knockout mouse.

Figure 5. Coexpression of miR-375 and miR-15a promotes growth of prostate carcinoma cell lines. A, DU145 or LNCaP cells were transfected either with control vector or miRNA expression vectors. The cells were harvested and counted by fluorescence-activated cell sorting (FACS) analysis at the indicated time points. B, DU145 cells were transfected either with control siRNA or miRNA inhibitors and counted by FACS analysis at the indicated time points. The proliferation assays were carried out in triplicate. Bars represent the standard error of the mean.
develops prostate carcinoma with a high penetrance (12). A downregulation of PHLP1 or PHLP2 could be detected in 11% of primary prostate carcinoma and in 37% of metastases (23, 36). Recently, it has been reported that both PHLP1 and PHLP2 are deleted or downregulated in combination with highly metastatic prostate carcinoma (22) or glioblastoma (37). PHLPs belong to a family of phosphatases that regulate protein kinases A, B (known as Akt), and C and ribosomal protein S6 kinase (RPS6K) negatively (23, 38). PHLP1 and PHLP2 are considered to be tumor suppressors because they suppress cell survival, both by inhibiting proliferative pathways and by promoting apoptotic pathways (23). PHLP in membrane rafts of rat brains can negatively regulate the proliferative RAS–mitogen-activated protein kinase (MAPK) pathway (39). Furthermore, human PHLP1 and PHLP2 can differentially regulate proliferative AKT signaling by selectively dephosphorylating the hydrophobic motifs of AKT2 or AKT3. Knockdown of PHLP1 specifically modulated phosphorylation of human double minute 2 (HDM2) and glycogen synthetase kinase 3 alpha (GSK3A) through AKT2, and PHLP2 specifically modulated phosphorylation of p27 (CDKN1B) through AKT3 (40). On the other hand, PHLP can act proapoptotic; when inactivating AKT, it catalyzes an activating dephosphorylation of the proapoptotic kinase MST1 (the human homologue of Hippo; 41, 42). Altogether, PHLPs affect major cancer pathways as RAS–MAPK, ABC protein kinases, and p53 (via HDM2 and p27) signaling, which have been described as also being significant in prostate cancer (23, 43).

The induction of miR-375 and miR-15a can contribute to the downregulation of PHLPs activity in prostate carcinoma. Although several studies did not notice an upregulation of miR-375 in prostate carcinoma samples, various studies observed increased levels of this miRNA in prostate cancer serum samples (44, 45). Publications confirm that miR-375 is downregulated in other cancer types such as cervical, lung, or head and neck carcinoma, as well as glioma (46–50) but upregulated in breast carcinoma (51). Likewise, miR-15a was previously shown to be downregulated in metastasizing prostate carcinoma (18). We observed an initial upregulation and a subsequent downregulation of miR-15a in the metastatic samples, albeit at levels above those detected in normal tissue. In two studies, an increase of miR-15a was found to be of negative predictive value in renal cell carcinoma (52) or diffuse large B-cell lymphoma (53). There are now large numbers of studies that established miRNA profiles of prostate carcinoma, which, to some extent, report conflicting results (reviewed in ref. 3). Our observation that miR-15a is increased in the different tumor stages examined is in contradiction with data presented by Bonci and colleagues, which described a downregulation of miR-15a in prostate carcinoma (18) in line with the notion that miR-15a (and miR-16) are tumor-suppressor miRNAs. Our previous study on intermediately aggressive prostate carcinoma (5) with Gleason scores of 6 or 7 yielded an upregulation in one and a downregulation in the parallel patient cohort (5). Our qRT-PCR analysis, however, showed a slight increase in miR-15a expression, which was not statistically significant though various other studies did not find a significant deregulation of miR-15a (34, 54, 55). The study by Amb sought an upregulation of miR-16, also at odds with the report by Bonci and colleagues (18). However, miR-15a is considered as tumor suppressor at inducing cell cycle arrest and apoptosis in prostate carcinoma (reviewed in ref. 6). A recent review on miRNAs and their influence on functional protein networks also predicted that miR-15a plays an inhibitory role for prostate cancer cell growth (56). We find that 10/21 miRNAs predicted in that publication (see, i.e., Fig. 3 in ref. 56) to play a role in tumorigenesis were also found in our analysis. This implies that a large number of bioinformatical predictions may be experimentally validated. There are different explanations for the often inconsistent results about miR-15a, in that they could be due to different methods employed, such as qRT-PCR, microarray, or cDNA sequencing.

Altogether, miRNA profiling of pT2 (pN0), pT3 (pN0), and lymph node metastasizing prostate carcinoma (pN1) by deep sequencing revealed clearly changed miRNA levels. Two miRNAs, miR-375 and miR-15a with high levels at all tumor stages detected by deep sequencing and Northern blotting, target the phosphatases PHLP1 and PHLP2, respectively. Both phosphatases PHLP1 and PHLP2 normally suppress survival pathways as AKT- and RAS–MAPK, which are aberrated in prostate carcinoma. Overexpression of miR-15a and miR-375 results in a downregulation of PHLP1/2 and an increase in prostate carcinoma cell growth. Our results disclose an association between miRNA regulation and major phosphatase pathways in prostate carcinoma development.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: M. Hart, S. Wach, F.A. Gräser, B. Wullich
Development of methodology: T.T. Rau
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S. Wach, T.T. Rau, A. Hartmann, B. Wullich
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M. Hart, E. Nolte, S. Wach, J. Szczyzba, H. Taubert, T.T. Rau, F.A. Gräser, B. Wullich
Writing, review, and/or revision of the manuscript: M. Hart, E. Nolte, S. Wach, H. Taubert, A. Hartmann, F.A. Gräser, B. Wullich
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): T.T. Rau, A. Hartmann
Study supervision: S. Wach, J. Szczyzba, F.A. Gräser, B. Wullich

Acknowledgments
The authors thank Ruth Nord for expert technical assistance and Gabrielle P. Cooper (MA) for language-editing service.

Grant Support
This work was supported by the Wilhelm-Sander-Stiftung by a grant 2007.025.01 (to B. Wullich and F.A. Gräser).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 8, 2013; revised October 21, 2013; accepted November 6, 2013; published OnlineFirst December 13, 2013.
References

41. Jiang SW, Yang SJ, Shinivasan S, Ye K. Akt phosphorylates Mat1 and prevents its proteolytic activation, blocking FOXO3

Mol Cancer Res; 12(2) February 2014

Molecular Cancer Research

Published OnlineFirst December 13, 2013; DOI: 10.1158/1541-7786.MCR-13-0230

Downloaded from mcr.aacrjournals.org on December 23, 2017. © 2014 American Association for Cancer Research.


